Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016

American Journal of Medicine

Volumn 129, Issue 7, 2016, Pages 661-666

  Epstein, Murray ^a   Duprez, Daniel A ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Aldosterone; Carotid baroreceptor stimulation; Mineralocorticoid receptor antagonists; Renal nerve denervation; Resistant hypertension; Spironolactone

Indexed keywords

ALDOSTERONE; CATECHOLAMINE; COLLAGEN; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ARTERIAL STIFFNESS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR MORTALITY; COLLAGEN SYNTHESIS; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; ELEVATED BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; HUMAN; KIDNEY DENERVATION; MORBIDITY; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRESSOR RESPONSE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; SLEEP DISORDERED BREATHING; TREATMENT REFUSAL; VASCULAR REMODELING; WHITE COAT HYPERTENSION; AGE; CHEMICALLY INDUCED; COMORBIDITY; DIABETES MELLITUS; HYPERKALEMIA; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; WATER-ELECTROLYTE IMBALANCE;

AGE FACTORS; ALDOSTERONE; BLOOD PRESSURE MONITORING, AMBULATORY; COMORBIDITY; DIABETES MELLITUS; HUMANS; HYPERKALEMIA; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENAL INSUFFICIENCY, CHRONIC; SPIRONOLACTONE; VASCULAR STIFFNESS; WATER-ELECTROLYTE IMBALANCE;

EID: 84962276527     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.01.039     Document Type: Review

References (41)

1. D.A. Calhoun, D. Jones, S. Textor, and et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension 51 2008 1403 1419
2. D. Achelrod, U. Wenzel, and S. Frey Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations Am J Hypertens 28 2015 355 361
3. M. Epstein, and D.A. Calhoun The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy Curr Hypertens Rep 9 2007 98 105
4. J.R. Sowers, A. Whaley-Connell, and M. Epstein Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension Ann Intern Med 150 2009 776 783
5. D.A. Duprez Aldosterone and the vasculature: mechanisms mediating resistant hypertension J Clin Hypertens (Greenwich) 9 1 Suppl 1 2007 13 18
6. D.A. Calhoun Hyperaldosteronism as a common cause of resistant hypertension Annu Rev Med 64 2013 233 247
7. W.B. White, J.R. Turner, D.A. Sica, and et al. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013 J Am Soc Hypertens 8 2014 743 757
8. B.M. Egan, Y. Zhao, R.N. Axon, W.A. Brzezinski, and K.C. Ferdinand Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008 Circulation 124 2011 1046 1058
9. C. Cuspidi, G. Macca, L. Sampieri, and et al. High prevalence of cardiac and extra- cardiac target organ damage in refractory hypertension J Hypertens 19 2001 2063 2070
10. S.D. Pierdomenico, D. Lapenna, A. Bucci, and et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension Am J Hypertens 18 2005 1422 1428
11. S.L. Daugherty, J.D. Powers, D.J. Magid, and et al. Incidence and prognosis of resistant hypertension in hypertensive patients Circulation 125 2012 1635 1642
12. S.S. Yoon, Q. Gu, T. Nwankwo, J.D. Wright, Y. Hong, and V. Burt Trends in blood pressure among adults with hypertension: United States, 2003 to 2012 Hypertension 65 2015 54 61
13. S.A. Oliveria, P. Lapuerta, B.D. McCarthy, G.J. L'Italien, D.R. Berlowitz, and S.M. Asch Physician-related barriers to the effective management of uncontrolled hypertension Arch Intern Med 162 2002 413 420
14. M. Ruzicka, and S. Hiremath Can drugs work in patients who do not take them? The problem of non-adherence in resistant hypertension Curr Hypertens Rep 17 2015 69 77
15. O. Jung, J.L. Gechter, C. Wunder, and et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis J Hypertens 31 2013 766 774
16. M. Tomaszewski, C. White, and P. Patel High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LCMS/MS) urine analysis Heart 100 2014 855 861
17. SPRINT Research Group J.T. Wright Jr., J.D. Williamson, P.K. Whelton, and et al. A randomized trial of intensive versus standard blood-pressure control N Engl J Med 373 2015 2103 2116
18. T.G. Pickering, J.E. Hall, L.J. Appel, and et al. Recommendations for blood pressure measurement in humans and animals. Part 1: Blood pressure measurement in humans Hypertension 45 2005 142 161
19. F.H. Messerli Osler's maneuver, pseudohypertension, and true hypertension in the elderly Am J Med 80 1986 906 910
20. Noncommunicable diseases: a major health challenge of the 21st century. In: World Heath Statistics 2012, ed. World Health Organization:34-37. Available at: www.who.int/gho/publications/world-health-statistics/2012/en/. Accessed January 27, 2016.
21. A.G. Logan, S.M. Perlikowski, A. Mente, and et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension J Hypertens 19 2001 2271 2277
22. C. Gonzaga, A. Bertolami, M. Bertolami, C. Amodeo, and D. Calhoun Obstructive sleep apnea, hypertension and cardiovascular diseases J Hum Hypertens 29 2015 705 712
23. M.N. Pratt-Ubunama, M.K. Nishizaka, R.L. Boedefeld, S.S. Cofield, S.M. Harding, and D.A. Calhoun Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension Chest 131 2007 453 459
24. D.A. Calhoun, and W.B. White Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension J Am Soc Hypertens 2 2008 462 468
25. K. Dahal, S. Kunwar, J. Rijal, and et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies Am J Hypertens 28 2015 1376 1385
26. H. Sternlicht, and G.L. Bakris Spironolactone for resistant hypertension-hard to resist? Lancet 386 2015 2032 2034
27. K. Gaddam, E. Pimenta, S.J. Thomas, and et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report J Hum Hypertens 24 2010 532 537
28. J. Václavík, R. Sedlák, and M. Plachy Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial Hypertension 57 2011 1069 1075
29. C.S. Oxlund, J.E. Henriksen, L. Tarnow, K. Schousboe, J. Gram, and I.A. Jacobsen Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial J Hypertens 31 2013 2094 2102
30. B. Williams, T.M. MacDonald, S. Morant, and et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial Lancet 386 2015 2059 2068
31. S. Lentini, R. Heinig, N. Kimmeskamp-Kirschbaum, and G. Wensing Safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies Fundam Clin Pharmacol 2015 Nov 25 [Epub ahead of print]
32. M. Epstein, M. Mayo, D. Garza, and et al. Patiromer controls hyperkalemia in resistant hypertensive patients on RAASi, with diabetic kidney disease Circulation 132 Suppl 3 2015 A14271
33. M.A. Weber, H. Black, G. Bakris, and et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial Lancet 374 2009 1423 1431
34. A. Briasoulis, and G. Bakris The future of interventional management of hypertension: threats and opportunities Curr Vasc Pharmacol 12 2014 69 76
35. R.G. Victor Carotid baroreflex activation therapy for resistant hypertension Nat Rev Cardiol 12 2015 451 463
36. J.D. Bisognano, G. Bakris, M.K. Nadim, and et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial J Am Coll Cardiol 58 2011 765 773
37. G.L. Bakris, M.K. Nadim, H. Haller, E.G. Lovett, J.E. Schafer, and J.D. Bisognano Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial J Am Soc Hypertens 6 2012 152 158
38. H. Krum, M. Schlaich, R. Whitbourn, and et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 2009 1275 1281
39. D.L. Bhatt, D.E. Kandzari, W.W. O'Neill, and et al. A controlled trial of renal denervation for resistant hypertension N Engl J Med 370 2014 1393 1401
40. M. Epstein, and E. de Marchena Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation? J Am Soc Hypertens 9 2015 140 149
41. J. Rosa, P. Widimský, P. Waldauf, and et al. Role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized PRAGUE-15 study Hypertension 67 2016 397 403